Stay updated on Fazirsiran in AATD Liver Disease Clinical Trial
Sign up to get notified when there's something new on the Fazirsiran in AATD Liver Disease Clinical Trial page.

Latest updates to the Fazirsiran in AATD Liver Disease Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoChange DetectedThe web page has been updated to include new details about the study of fazirsiran (TAK-999, ARO-AAT), including specific dosing regimens, study periods, and various metrics for evaluating liver health. Additionally, the results reporting dates have been clarified.SummaryDifference100%
- Check22 days agoChange DetectedThe page has undergone significant content removal, particularly regarding the study details for fazirsiran (TAK-999, ARO-AAT) related to Alpha-1 Antitrypsin Deficiency, including the study's purpose, participant criteria, and treatment procedures. The revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference12%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
Stay in the know with updates to Fazirsiran in AATD Liver Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fazirsiran in AATD Liver Disease Clinical Trial page.